Protara Therapeutics, Inc. (TARA) Cash Flow Statement

Because net losses are broadly matched by operating cash outflows, the earnings base for this company carries little accrual noise that would flatter or penalize reported results. The 2026Q2 narrowing of the ratio to 0.65 appears to reflect a working capital inflow of $6.4M rather than any improvement in underlying spending. Investors should monitor whether that inflow reverses, as it may indicate timing benefits rather than sustained cash discipline.

The FCF margin cannot be computed given zero reported revenue, so the analysis rests entirely on absolute burn rates. Quarterly deficits have ranged from roughly $7.7M to $21.3M without a clear downward trend, suggesting spending has not contracted meaningfully. This pattern implies continued reliance on external funding, though the supplied data does not describe available liquidity or financing terms.

Capex intensity is effectively zero relative to the scale of operating losses, so capital spending does not explain the cash burn. The gap between the 2026Q2 capex of $332K and depreciation of $72K may indicate a modest investment in equipment or facilities, though its scale is too small to alter the overall cash profile. The primary drivers of burn are operating costs, particularly R&D, rather than physical asset investment.

With negative free cash flow in every period, there is no internally generated capital available for distributions or buybacks, and the minimal repurchase activity appears immaterial. Cash deployment is effectively limited to funding operating losses. Investors should monitor future financing activity, as the supplied data does not disclose cash balances or financing arrangements that would confirm the runway.